07:00 , Sep 10, 2001 |  BC Week In Review  |  Company News

Calydon, Cell Genesys deal

CEGE completed its acquisition of private cancer company Calydon for 935,000 CEGE shares valued at $17 million based on CEGE's Friday close at $18.20 (see BioCentury, Aug. 6). Calydon Inc., Sunnyvale, Calif.   Cell Genesys...
07:00 , Sep 10, 2001 |  BioCentury  |  Analyst Picks & Changes

Analyst picks & changes

Cell Genesys Inc. (CEGE), Foster City, Calif. Business: Gene/Cell therapy, Cancer, Neurological Needham & Co. analyst Mark Monane raised his price target to $30-$32 from $24-$26. He said CEGE's completion of its acquisition of Calydon...
07:00 , Aug 6, 2001 |  BC Week In Review  |  Company News

Calydon, Cell Genesys deal

CEGE will acquire Calydon for about 935,000 CEGE shares valued at $17.4 million based on a 30 trading day closing price average ending July 31. CEGE, which also will assume $2.6 million in Calydon liabilities,...
07:00 , Aug 2, 2001 |  BC Extra  |  Company News

Cell Genesys to acquire Calydon

CEGE will acquire Calydon (Sunnyvale, Calif.) for about 935,000 CEGE shares valued at $17.4 million based on a 30 trading day closing price average ending July 31. CEGE, which also will assume $2.6 million in...
07:00 , Jul 2, 2001 |  BC Week In Review  |  Company News

Triad management update

Triad Therapeutics Inc., San Diego, Calif.   Business: Chemistry   Hired: Christine Gray-Smith as CFO, formerly VP of finance and CFO at Calydon Inc.  ...
08:00 , Jan 22, 2001 |  BC Week In Review  |  Company News

Calydon other research news

Calydon researchers published in Cancer Research that CV787 combined with either Taxotere docetaxel or Taxol paclitaxel was synergistic in cytoxicity against prostate cancer cells as measured in a human prostate cancer cell line and in...
08:00 , Dec 18, 2000 |  BC Week In Review  |  Clinical News

Tumor-specific viruses regulatory update

Calydon received U.S. Patents Nos. 6,057,299; 6,051,417; and 6,136,792 covering a human prostate-specific antigen enhancer (PSE) and a human glandular kallikrein enhancer (GKE) that regulate expression of genes in prostate cells. Calydon said the transcriptional...
08:00 , Oct 30, 2000 |  BC Week In Review  |  Clinical News

CN706: Phase I/II

In a U.S. Phase I/II trial of 20 men who had failed radiation therapy, PSA levels decreased from baseline in 9 of 11 patients in the 2 highest dose groups. Of those 9, 4 patients...
07:00 , Oct 2, 2000 |  BC Week In Review  |  Clinical News

CV787: Began Phase I/II study

Calydon Inc., Sunnyvale, Calif.   Product: CV787   Business: Cancer   Therapeutic category: Cytotoxic   Target: Cells expressing PSA   Description: Intravenous second generation engineered virus containing human prostate-specific enhancer/promoter and rat probasin promoter elements...
07:00 , Sep 11, 2000 |  BC Week In Review  |  Company News

Cell Genesys management update

Cell Genesys Inc. (CEGE), Foster City, Calif.   Business: Cancer, Gene/Cell therapy, Infectious diseases   Hired: Robert Tidwell as VP of corporate development, formerly VP of business development at Calydon Inc. , replacing Bruce Hironaka...